• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Organon & Co. (NY: OGN )

    16.92 -1.15 (-6.36%)
    Official Closing Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Organon & Co.

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Why Merck's Strong Outlook For 2021 Could Become Even More Bullish
    Merck issued upbeat guidance for 2021 that could grow if Covid pill molnupiravir gains authorization. 
    Via Investor's Business Daily
    Organon To Report Third Quarter Results and Host Conference Call on November 11, 2021
    From Organon & Co.
    Via Business Wire
    Europe's Unicorns
    After markets jumped yesterday, we saw a lot of bounce today although gold fell back a bit. 
    Via Talk Markets
    Organon Launches New Fertility Journey Website as Part of Ongoing Commitment to Help Address the Needs of Women
    From Organon & Co.
    Via Business Wire
    Expert Ratings For Organon
    Analysts have provided the following ratings for Organon (NYSE:OGN) within th... 
    Via Benzinga
    What 6 Analyst Ratings Have To Say About Organon
    Organon (NYSE:OGN) has observed the following analyst ratings within the last... 
    Via Benzinga
    Organon Receives FDA Clearance for Technological Updates to the Jada® System, a Medical Device Intended to Control Postpartum Hemorrhage
    From Organon & Co.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021
    Upgrades For State Street Corporation (NYSE: 
    Via Benzinga
    The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
    Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
    Via Benzinga
    Exposures Product Safety
    Unusual Options Activity Insight: UP Fintech Holding
    Organon (NYSE:OGN) shares experienced unusual options activi... 
    Via Benzinga
    Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy
    From Organon & Co.
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2021
    Upgrades For Chatham Lodging Trust (NYSE: 
    Via Benzinga
    Organon To Present at Morgan Stanley’s 19th Annual Global Healthcare Virtual Conference
    From Organon & Co.
    Via Business Wire
    Organon To Present at Citi’s 16th Annual BioPharma Virtual Conference
    From Organon & Co.
    Via Business Wire
    Top Stocks Warren Buffett Just Bought
    These were Berkshire Hathaway's biggest buys during Q2, 2021. 
    Via The Motley Fool
    Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios
    The latest round of 13F filings from institutional investors is out, revealing to the world the stocks that some of the richest and most successful investors have been buying and... 
    Via Benzinga
    Friday the Thirteenth
    The stock week in points eastward was mixed. The USA markets face a bear correction. 
    Via Talk Markets
    Merck Spinoff Organon Just Reported Its First Quarter — Here's What You Need To Know
    Organon crushed Wall Street's second-quarter expectations on Thursday and announced its first dividend, leading OGN stock to pop. 
    Via Investor's Business Daily
    Organon Reports Results for the Second Quarter Ended June 30, 2021 and Announces Inaugural Dividend
    From Organon & Co.
    Via Business Wire
    ObsEva Stock Surges On Potential $500M Ebopiprant Deal For Preterm Labor
    Organon & Co (NYSE: OGN) will license the global development, manufacturing, and commercial rights to ObsEva SA's (NASDAQ: OBSV) ebopiprant (OBE022)... 
    Via Benzinga
    The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
    Via Benzinga
    Exposures Product Safety
    Earnings Scheduled For August 12, 2021
    Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
    Via Benzinga
    The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
    Via Benzinga
    Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
    From Organon
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021
    Upgrades Craig-Hallum upgraded the previous rating for Lindblad Expeditions Holdings Inc (NAS... 
    Via Benzinga
    Joblessness Surprise
    Despite higher production for the Emirates the price of oil rose sharply today. More output should cut prices. 
    Via Talk Markets
    Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021
    Upgrades According to Stephens & Co., the prior rating for World Acceptance Corp (NASDAQ:... 
    Via Benzinga
    Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021
    From Organon & Co.
    Via Business Wire
    Why Ocugen Shares Are Rallying Today
    Ocugen, Inc. (NASDAQ: OCGN) shares were advancing strongly Thursday after the biopharma issued a regulatory update. Pennsylvania-based Ocugen said it has initiated a rolling... 
    Via Benzinga
    3 Stocks I'd Avoid at All Costs
    On the surface, these companies seem like underpriced investments, but look a little closer and there's a good reason to stay away. 
    Via The Motley Fool
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.